Bedaquiline reloading strategies following interruptions during daily dosing
Year: 2026
Type: article
Abstract: Once-daily bedaquiline therapy is a WHO-listed alternative to thrice-weekly dosing for rifampicin-resistant tuberculosis, but, contrary to the thrice-weekly schedule, no guidance exists for treatment re-initiation after interruption. Using a population pharmacokinetic model, we simulated bedaquiline and M2 exposure under various interruption and reloading scenarios. Reloading strategies tailored to interruption duration restored bedaquiline exposure without clinically relevant increases in M2 peak concentrations, providing practical guidance for safe and effective treatment resumption of once-daily bedaquiline therapy.
DOI: 10.1128/aac.00063-26
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: City University of New York, Wellcome Trust, National Institutes of Health, Center for AIDS Research, University of Washington, National Institute of Allergy and Infectious Diseases, Einstein-Rockefeller-CUNY Center for AIDS Research, Albert Einstein College of Medicine, Wellcome Centre for Infectious Diseases Research in Africa
Awards: G144555574, G2198174088, G2542180245, G3266033856, Centre for Infectious Diseases Research in Africa (CIDRI-Africa), G4517903627, G5522199286, G9000099115, G9000281466, Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistant TB therapy in a high HIV prevalence setting, Mentoring of multidisciplinary global health research in tuberculosis and HIV
OpenAlex ID: W7159029302